394 related articles for article (PubMed ID: 30229376)
1. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
2. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
Gonçalves E
Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
[TBL] [Abstract][Full Text] [Related]
3. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
4. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
5. Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Qiu T; Liang S; Wang Y; Dussart C; Borissov B; Toumi M
Front Public Health; 2021; 9():754482. PubMed ID: 34900902
[TBL] [Abstract][Full Text] [Related]
6. Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs).
Spoors J; Miners A; Cairns J; Palnoch D; Summerfield A; McEntee J; Vithlani S
BioDrugs; 2021 Jan; 35(1):1-5. PubMed ID: 33226582
[TBL] [Abstract][Full Text] [Related]
7. Managing access to advanced therapy medicinal products: Challenges for NHS Wales.
Champion AR; Lewis S; Davies S; Hughes DA
Br J Clin Pharmacol; 2021 Jun; 87(6):2444-2449. PubMed ID: 32495405
[TBL] [Abstract][Full Text] [Related]
8. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
9. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.
Coyle D; Durand-Zaleski I; Farrington J; Garrison L; Graf von der Schulenburg JM; Greiner W; Longworth L; Meunier A; Moutié AS; Palmer S; Pemberton-Whiteley Z; Ratcliffe M; Shen J; Sproule D; Zhao K; Shah K
Eur J Health Econ; 2020 Dec; 21(9):1421-1437. PubMed ID: 32794011
[TBL] [Abstract][Full Text] [Related]
10. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
11. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
12. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
[TBL] [Abstract][Full Text] [Related]
13. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
14. New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing.
Pani L; Becker K
Clin Drug Investig; 2021 Jun; 41(6):529-537. PubMed ID: 34014509
[TBL] [Abstract][Full Text] [Related]
15. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
16. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
17. Reported Challenges in Health Technology Assessment of Complex Health Technologies.
Hogervorst MA; Vreman RA; Mantel-Teeuwisse AK; Goettsch WG
Value Health; 2022 Jun; 25(6):992-1001. PubMed ID: 35667787
[TBL] [Abstract][Full Text] [Related]
18. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of economic evaluations of advanced therapy medicinal products.
Lloyd-Williams H; Hughes DA
Br J Clin Pharmacol; 2021 Jun; 87(6):2428-2443. PubMed ID: 32154598
[TBL] [Abstract][Full Text] [Related]
20. Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries.
Gozzo L; Romano GL; Romano F; Brancati S; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():755052. PubMed ID: 34690785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
